Remove Conditions Remove Epilepsy Remove Pharmaceutical
article thumbnail

Study Finds That Non-Pharmaceutical May Boost Quality Of Life Among Epilepsy Patients

Veriheal

Patients who suffer from epilepsy , which affects some 3.4 This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. CBD, which constitutes a $2,770.8

article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Serious Conditions Are Responding To Cannabinoid Therapy

Peninsula Alternative Health

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because cannabis is still a schedule 1 drug in the U.S.,

article thumbnail

Marijuana as a treatment for epilepsy

Cannabis Info

Marijuana as a treatment for epilepsy. Medical cannabis is showing great potential in the treatment of epilepsy. Cannabis is issued medicinally for a plethora or disorders, and one that it seems to affect very positively is epilepsy. WHAT EXACTLY IS EPILEPSY? CONVENTIONAL TREATMENT. CANNABIS AS A POTENTIAL TREATMENT.

article thumbnail

Three Major Australian Medical Cannabis Companies Fined By The TGA “over claims prescriptions could treat conditions such as cancer and epilepsy”

Cannabis Law Report

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration has issued 73 infringement notices totalling $972,360 to licensed medicinal cannabis companies, MGC Pharmaceuticals Ltd (23 notices, $306,360).

article thumbnail

MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

Cannabis Law Report

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes.

article thumbnail

Second Edition Pharmaceutical Cannabis Report 2021: Featuring Almirall, Bayer and Novartis Among Others – ResearchAndMarkets.com

Cannabis Law Report

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals.